Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial

Table 1 Baseline characteristics of children at enrolment in a clinical trial of the efficacy of three artemisinin-containing combinations therapies with amodiaquine + sulphadoxine–pyrimathamine (AQ-SP)

	AS-SMP	AS-AQ	AL	AQ-SP	p
	N = 58	N = 68	N = 60	N = 65	p
Age (months)					0.396
Median	43	34	40	36
Interquartile range	27-51	25-49	27-48	23-52
Minimum, maximum	7-59	7-59	3-58	2-59
Gender					0.235
Male (n (%))	27 (47%)	39 (57%)	38 (63%)	32 (49%)
P. falciparum(/μl)					0.853
Median	17 000	18 509	16 471	14 400
Interquartile range	8200-60 000	6480-9 814	7200-58917	8000-36 000
Temperature at day 0 (°C)					0.198
Median	38,7	38.9	39.2	39.1
Interquartile range	38.3-39.7	38.3-39.9	38.4-40.2	38.4-39.7

AS-SMP, Artesunate + sulphamethoxypyrazine-pyrimethamine (Coarinate®); AS-AQ, Artesunate + amodiaquine (Coarsucam®); AL, Artemether + lumefantrine (Coartem®); AQ + SP, Amodiaquine + sulphadoxine-pyrimethamine; N, Effective number.

ISSN: 1475-2875